Cyclacel Pharma (CYCC) Reports Q3 Loss of $0.86/Share
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Research and development: 2.41M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 2.41M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.86), versus ($0.95) reported last year. Revenue for the quarter came in at $715 thousand, versus $205 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS says bull market has further to run
- Redwood Trust (RWT) PT Lowered to $6.50 at UBS Amid Legacy Portfolio Wind-Down
- PennyMac Mortgage Investment Trust (PMT) PT Lowered to $10 by UBS on Lower MSR Earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
